RPTX / Repare Therapeutics Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Employment Agreement between the registrant and Sandra Alves, dated May 28, 2025.

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of the date hereof, by and between Sandra Alves (the “Executive”) and Repare Therapeutics Inc. (the “Company” or “Repare”). WHEREAS, the Company and the Executive wish to enter into this Agreement to set forth the terms and conditions of the Executive’s continued employment with the Company effective M

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

Sixth Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics USA Inc. and Bristol-Myers Squibb Company, dated June 13, 2025.

Exhibit 10.2 EXECUTION COPY CONFIDENTIAL [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. SIXTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Sixth Amendment to Collaboration and License Agreement (this “Sixth Amendment”) is entered into a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Entered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value Initial data for

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Entered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value Initial data for LIONS and POLAR trials expected to be reported in Q4 2025 $109.5 million in cash and cash equivalents and marketable securities CAMBRIDG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 Repare Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

Exhibit 99.1 Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib July 15, 2025 CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)-Jul. 15, 2025— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm Intern

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Repare Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Repare Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Separation and Release Agreement between the registrant and Lloyd M. Segal dated March 31, 2025.

Exhibit 10.2 SEPARATION AND RELEASE AGREEMENT BETWEEN: REPARE THERAPEUTICS INC.; (the “Company”) AND: LLOYD M. SEGAL; (the “Executive”) WHEREAS the Executive has served as the Chief Executive Officer of the Company since September 2016; WHEREAS the parties are currently engaged in an employment relationship pursuant to an employment agreement executed on June 12, 2020 (the “Employment Agreement”);

Amendment to Employment Agreement for Steve Forte as of March 31, 2025.

Exhibit 10.1 Amendment to the EMPLOYMENT AGREEMENT This Amendment to the Employment Agreement (the "Amendment") is entered into as of March 31, 2025 (the “Effective Date of the Amendment”), by and between Steve Forte (the "Executive") and Repare Therapeutics Inc. (the "Company"). Whereas the Company and the Executive entered into an employment agreement dated June 12, 2020 (the "Employment Agreeme

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results Exploring strategic alternatives to advance clinical stage pipeline and maximize shareholder value $124.2 million in cash and cash equivalents

Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results Exploring strategic alternatives to advance clinical stage pipeline and maximize shareholder value $124.2 million in cash and cash equivalents and marketable securities provides runway as of March 31, 2025 CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—May 13, 2025 — Repare Therapeu

Transition and Separation Agreement between the registrant and Maria Koehler dated February 24, 2025.

Exhibit 10.3 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the “Agreement”) is made by and between Maria Koehler (“Employee” or “you”) and Repare Therapeutics USA Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee has been employed by the Company as its Executive Vice President and Ch

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Exhibit 99.1 Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—May 1, 2025— Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Repare Therapeutics Announces Leadership Transitions Steve Forte, Executive Vice President and Chief Financial Officer, appointed as President, Chief Executive Officer and Director Lloyd M. Segal has resigned as President, Chief Executive Officer and

Exhibit 99.1 Repare Therapeutics Announces Leadership Transitions Steve Forte, Executive Vice President and Chief Financial Officer, appointed as President, Chief Executive Officer and Director Lloyd M. Segal has resigned as President, Chief Executive Officer and Director to pursue other opportunities CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—March 31, 2025— Repare Therapeutics Inc. (“Repare” or

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

Warrant to Purchase Common Shares issued to Astr Partners LLC, dated November 7, 2024.

Exhibit 4.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. REPARE THERAPEU

Filing fee table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, no par value per share, 2020 Equity Incentive Plan Other(2) 2,125,535(4) $1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu

As filed with the Securities and Exchange Commission on March 3, 2025

As filed with the Securities and Exchange Commission on March 3, 2025 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

Repare Therapeutics Inc. Insider Trading Policy

Exhibit 19.1 REPARE THERAPEUTICS INC. INSIDER TRADING POLICY Introduction During the course of your relationship with Repare Therapeutics Inc. (the “Company”), you may receive material information that is not yet publicly available ( “material nonpublic information”) about the Company or about other publicly traded companies with which the Company has business relationships with. Material nonpubli

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results Initial clinical readout from Phase 1 RP-3467 (Polq ATPase/helicase inhibitor) POLAR trial expected in Q3 2025 Initial clinical

Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results Initial clinical readout from Phase 1 RP-3467 (Polq ATPase/helicase inhibitor) POLAR trial expected in Q3 2025 Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025 Company reducing its workforce by approximately 75% $152.8

Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2025 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

Joint Filing Statement

Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc.

Joint Filing Statement

Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc.

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polq ATPase inhibitor), wit

Exhibit 99.1 Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polq ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring partnerships for continued development of Lunre+Camo and other assets

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

Joint Filing Statement

Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc.

Schedule I General Partners/Members

Schedule I General Partners/Members Ansbert Gadicke c/o BioImpact 399 Boylston Street, Suite 1100 Boston, MA 02116 Principal Occupation: Managing director of MPM BioVentures 2014 LLC and managing partner of MPM BioImpact LLC.

Joint Filing Statement

Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc.

MYTHIC Lunre+Camo Clinical Data Update December 12, 2024

Exhibit 99.2 MYTHIC Lunre+Camo Clinical Data Update December 12, 2024 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “projects,”

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall r

EX-99.1 Exhibit 99.1 Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic

RPTX / Repare Therapeutics Inc. / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-rptx093024a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Repare Therapeutics Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro

RPTX / Repare Therapeutics Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm2427858d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Repare therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap

Joint Filing Agreement

EX-99.1 2 tm2427858d9ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Shares, no par

RPTX / Repare Therapeutics Inc. / Blue Owl Capital Holdings LP - SC 13G/A Passive Investment

SC 13G/A 1 ef20038682sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Repare Therapeutics Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the Ap

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results On track to report data from the ongoing MYTHIC dose expansion clinical trial at the recommended Phase 2 dose (RP2D) at a company event in Dece

Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results On track to report data from the ongoing MYTHIC dose expansion clinical trial at the recommended Phase 2 dose (RP2D) at a company event in December 2024, with the plan to begin a registrational trial in 2025 Presented updated positive safety and tolerability results from the Phas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Up to $100,000,000 Common Shares

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281298 PROSPECTUS SUPPLEMENT (to Prospectus dated August 19, 2024) Up to $100,000,000 Common Shares We have entered into a sales agreement, or the sales agreement, with TD Securities (USA) LLC, or TD Cowen, relating to our common shares, no par value per share, offered by this prospectus supplement and the accompanying prospec

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

Common Shares Sales Agreement, dated November 4, 2024, by and between Repare Therapeutics Inc. and TD Securities (USA) LLC.

Exhibit 10.2 Repare therapeutics inc. Common Shares SALES AGREEMENT November 7, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Repare Therapeutics Inc., a corporation continued under the Business Corporations Act (Québec) (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and

First Amendment to the Lease Agreement by and between the registrant, Repare Therapeutics Inc. and RREEF America REIT II Corp. PPP, dated August 26, 2024

Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) dated as of August 26, 2024 (the “Effective Date”), between RREEF AMERICA REIT II CORP. PPP, a Maryland corporation (“Landlord”), and REPARE THERAPEUTICS USA, INC., a Delaware corporation (“Tenant”), related to certain premises located in the building in Riverfront Office Park, Cambridge, Massachusetts at

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio Focuses Company’s resources on its deep clinical oncology pipeline Positioned to advance four clinical programs through multiple upcoming milestones

Exhibit 99.1 Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio Focuses Company’s resources on its deep clinical oncology pipeline Positioned to advance four clinical programs through multiple upcoming milestones CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)—Aug. 28, 2024—Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinica

REPARE THERAPEUTICS INC. 7171 Frederick-Banting, Building 2 Suite 270 St-Laurent, Québec H4S 1Z9

REPARE THERAPEUTICS INC. 7171 Frederick-Banting, Building 2 Suite 270 St-Laurent, Québec H4S 1Z9 Canada August 15, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Repare Therapeutics Inc. Registration Statement on Form S-3 File No. 333-281298 Ladies and Gentlemen: In accordance with Rule 461 under the Securities A

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.9 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REPARE THERAPEUTICS INC., a corporation organized under the laws of the province of Québec (the “Company”), and [•], a [corporation] [n

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results Reiterated guidance on data readout from MYTHIC trial evaluating lunresertib and camonsertib in patients with platinum-resistant ovarian and e

Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results Reiterated guidance on data readout from MYTHIC trial evaluating lunresertib and camonsertib in patients with platinum-resistant ovarian and endometrial cancers in Q4 2024 Granted Fast Track designation by the FDA for lunresertib in combination with camonsertib in platinum-resis

Power of Attorney (included on signature page).

Table of Contents As filed with the Securities and Exchange Commission on August 6, 2024 Registration No.

Form of Indenture between the Registrant and one or more trustees to be named.

Exhibit 4.5 REPARE THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Se

Form of Preferred Share Warrant Agreement and Warrant Certificate.

Exhibit 4.8 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF PREFERRED SHARE WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF PREFERRED SHARE WARRANT AGREEMENT THIS PREFERRED SHARE WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REPARE THERAPEUTICS INC., a corporation existing under the laws of the province of Québec (the “Company”), and [•], a [corporation] [na

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Repare Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Form of Common Share Warrant Agreement and Warrant Certificate.

Exhibit 4.7 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF COMMON SHARE WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF COMMON SHARE WARRANT AGREEMENT THIS COMMON SHARE WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REPARE THERAPEUTICS INC., a corporation existing under the laws of the province of Québec (the “Company”), and [•], a [corporation] [national ba

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio

Form of Restricted Stock Unit Grant Notice and Award Agreement for the Repare Therapeutics Inc. 2024 Inducement Plan.

Exhibit 99.3 US Standard Form REPARE THERAPEUTICS INC. 2024 INDUCEMENT PLAN RESTRICTED SHARE UNIT GRANT NOTICE Repare Therapeutics Inc. (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Share Unit Award for the number of shares of the Company’s Common Shares (“Restricted Share Units”) set forth below (the “Award”). The Award is subject to

Repare Therapeutics Inc. 2024 Inducement Plan

Exhibit 99.1 REPARE THERAPEUTICS INC. 2024 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 25, 2024 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 56

Form of Stock Option Grant Notice and Stock Option Agreement for the Repare Therapeutics Inc. 2024 Inducement Plan.

Exhibit 99.2 US Standard Form REPARE THERAPEUTICS INC. 2024 INDUCEMENT PLAN STOCK OPTION GRANT NOTICE Repare Therapeutics Inc. (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of the Company’s Common Shares set forth below. This option is granted in compliance with Nasdaq Listing Rule 5635(c)(4) as a material inducem

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Repare Therapeutics Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares,  no par value per  share  Other   350,000(2)   $3.17(3)    $1,109,500    0.

As filed with the Securities and Exchange Commission on May 24, 2024

As filed with the Securities and Exchange Commission on May 24, 2024 Registration No.

Insight that enriches. Precision that empowers. Corporate Presentation May 2024

Insight that enriches. Precision that empowers. Corporate Presentation May 2024 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potential,” "projects,” “

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continu

Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in co

Fifth Amendment to Collaboration and License Agreement by and between the registrant and Bristol-Myers Squibb Company, dated March 14, 2024.

Exhibit 10.1 [***] Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation SK. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Fifth Amendment to Collaboration and License Agreement (this “Fifth Amendment”) is entered into as of March 14, 2024 (the

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

Exhibit 99.1 Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors CAMBRIDGE, MA & MONTREAL, QC (BUSINESS WIRE)—April 26, 2024— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Repare Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—February 28, 2024— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023

Incentive Compensation Recoupment Policy of Repare Therapeutics Inc.

Exhibit 97 Repare Therapeutics Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Repare Therapeutics Inc., a corporation continued under the Business Corporations Act (Québec) (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”)

As filed with the Securities and Exchange Commission on February 28, 2024

As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.

Filing fee table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1 — Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, no par  value per share, 2020 Equity Incentive Plan Other(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu

Joint Filing Agreement

EX-99.1 2 tm245846d10ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Shares, no par

RPTX / Repare Therapeutics Inc. / Blue Owl Capital Holdings LP - SC 13G Passive Investment

SC 13G 1 ef20021764sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Repare Therapeutics Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the Appropria

RPTX / Repare Therapeutics Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm245846d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Repare therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app

RPTX / Repare Therapeutics Inc. / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-rptx123123a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Repare Therapeutics Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp

Repare Therapeutics to Regain Global Rights to Camonsertib Repare will regain control of its potential best-in-class oral small molecule ATR inhibitor

Exhibit 99.1 Repare Therapeutics to Regain Global Rights to Camonsertib Repare will regain control of its potential best-in-class oral small molecule ATR inhibitor CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)—Feb. 12, 2024—Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will regain global development a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Repare Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis

RPTX / Repare Therapeutics Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis

Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment

Exhibit 99.1 Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment January 25, 2024 Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial Repare is eligible to receive up to $1.2 billion in potential milestones, plus royalties on global net product sales CAMBRIDGE, Mass. & MONTREAL

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Exhibit 99.1 Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones January 8, 2024 CAMBRIDGE, Mass. & MONTREAL—(BUSINESS WIRE)—Jan. 8, 2024—Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. “We significa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Repare Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

RPTX / Repare Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment

SC 13D/A 1 sc13da107422rptx11172023.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Repare Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polq Inhibitor RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-hi

EX-99.1 Exhibit 99.1 Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polq Inhibitor RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARP

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an ov

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare to host conference call and webcast to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

RPTX / Repare Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) JAMES KRATKY BVF PARTNERS

JOINT FILING AGREEMENT

EX-99.1 2 ex991to13d07422rptx11032023.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated November 3, 2023 (including amendments thereto) with respect to the Common Shares, no par

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Repare Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis

Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates,"

Insight that enriches. Precision that empowers. Corporate Presentation October 2023 Exhibit 99.2 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potentia

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across mul

Exhibit 99.1 Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and 50% RECIST response in patients with he

Agenda Welcome & Introduction Lloyd M. Segal, President & CEO Lunresertib Preliminary MYTHIC Monotherapy & Combination Therapy Clinical Trial Results Timothy Yap, MBBS, PhD, FRCP, Principal Investigator, MYTHIC Trial Conclusions & Lunresertib Develop

Insight that enriches. Precision that empowers. Lunresertib MYTHIC Clinical Trial Update October 13, 2023 Exhibit 99.1 Agenda Welcome & Introduction Lloyd M. Segal, President & CEO Lunresertib Preliminary MYTHIC Monotherapy & Combination Therapy Clinical Trial Results Timothy Yap, MBBS, PhD, FRCP, Principal Investigator, MYTHIC Trial Conclusions & Lunresertib Development Plan Maria Koehler, MD, Ph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 Repare Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alt

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistance Roche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2

Form of Amendment to Executive Employment Agreement

Exhibit 10.2 Amendment to Employment Agreement This Amendment to the Employment Agreement (the “Amendment”) is entered into as of July 13, 2023 (the “Effective Date”), by and between [](the “Executive”) and [Repare Therapeutics Inc.] [Repare Therapeutics USA Inc.] (the “Company”). Recitals A. Effective [],the Company and the Executive entered into an employment agreement (the “Employment Agreement

Fourth Amendment to Collaboration and License Agreement by and between the registrant and Repare Therapeutics USA Inc. and Bristol-Myers Squibb Company, dated May 12, 2023

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE REPARE THERAPEUTICS INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REPARE THERAPEUTICS INC. IF PUBLICLY DISCLOSED. FOURTH AMENDMENTTO COLLABORATION AND LICENSEAGREEMENT This Fourth Amendment to Collaboration and License Agreeme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Repare Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials Findings from the ongoing Phase 1 MYTHIC study demonstrat

EX-99.1 Exhibit 99.1 Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, includin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Repare Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

As filed with the Securities and Exchange Commission on May 30, 2023

S-8 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No.

Filing fee table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, no par value per share Other(2) 240,000(3) $9.83 $2,359,20

Inducement Award Agreement between Repare Therapeutics Inc. and Daniel Belanger, dated May 18, 2023.

EX-99.1 Exhibit 99.1 REPARE THERAPEUTICS INC. STOCK OPTION GRANT NOTICE (NONSTATUTORY STOCK OPTION GRANTED OUTSIDE OF THE 2020 EQUITY INCENTIVE PLAN) Repare Therapeutics Inc. (the “Company”) hereby grants to Optionholder an option to purchase the number of the Company’s Common Shares set forth below. This option is granted outside of the Company’s 2020 Equity Incentive Plan (the “Plan”), but shall

Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meet

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Lease Amendment Agreement No.1 by and between the registrant Repare Therapeutics Inc. and NEOMED Institute dated April 1, 2023

EXHIBIT 10.1 [***] Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. LEASE AMENDMENT AGREEMENT No 1 dated effective April 1, 2023 BETWEEN: NEOMED INSTITUTE, duly incorporated under Canada Not-for-profit Corporations Act, having received its certifica

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors

EX-99.1 Exhibit 99.1 Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors CAMBRIDGE, MA & MONTREAL, QC (BUSINESS WIRE)—April 28, 2023— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting Camonsertib PARPi combinations demonstrated 48% CBR in pati

EX-99.1 Exhibit 99.1 Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting Camonsertib PARPi combinations demonstrated 48% CBR in patients with unmet medical needs, across tumor types, and regardless of PARPi partner or platinum resistance, with a favorable safet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Repare Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

Power of Attorney (included on the signature page of this Form S-8).

S-8 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.

Filing fee table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, no par value per share, 2020 Equity Incentive Plan Other(2

Second Amendment to Research Services, License and Collaboration Agreement by and between the registrant, Repare Therapeutics Inc. and Ono Pharmaceutical., Ltd, dated January 31, 2023.

EXHIBIT 10.33 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. SECOND AMENDMENT TO RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT This Second Amendment to Research Services, License and Collaboration Agreement (this “Second Amendment”) is

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—February 28, 2023— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu

Lease Amending Agreement by and between the registrant, Repare Therapeutics Inc. and NEOMED Institute, dated October 27, 2022.

EXHIBIT 10.31 LEASE AMENDING AGREEMENT THIS AGREEMENT is entered into in the city of Montreal (Quebec) as of this October 27th, 2022 (the “Effective Date”). BY AND BETWEEN: NEOMED INSTITUTE, a corporation governed by the Canada Not-for-profit Corporations Act, having its principal place of business at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, herein acting and represe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

Lease Agreement by and between the registrant, Repare Therapeutics Inc. and NEOMED Institute, dated January 1, 2023.

EXHIBIT 10.32 AGREEMENT OF LEASE MADE AND ENTERED INTO IN THE CITY OF MONTREAL, PROVINCE OF QUEBEC, THIS 1st DAY OF JANUARY 2023. BY AND BETWEEN: NEOMED INSTITUTE, a corporation governed by the Canada Not-for-profit Corporations Act, having its principal place of business at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, herein acting and represented by Matthew Carlyle, CF

RPTX / Repare Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm236041d17sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Repare therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appr

Joint Filing Agreement

EX-99.1 2 tm236041d17ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, no par v

RPTX / Repare Therapeutics Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

RPTX / Repare Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 5 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31,

RPTX / Repare Therapeutics Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment

SC 13G/A 1 rptxa221323.htm CHI ADVISORS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Repare Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the a

RPTX / Repare Therapeutics Inc / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

RPTX / Repare Therapeutics Inc / Versant Venture Capital V, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* REPARE THERAPEUTICS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 760273102 (CUSIP Number) Versant Venture Capital V, L.P. Max Eisen

Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results Early Phase 1 clinical data readout for RP-6306 is expected in the first half of 2023 Advancing camonsertib development with Roche under worldwide license a

Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results Early Phase 1 clinical data readout for RP-6306 is expected in the first half of 2023 Advancing camonsertib development with Roche under worldwide license and collaboration agreement IND-enabling studies for RP-2119, a Pol? inhibitor, currently underway and on track for trial start in summer 2023 Well positioned to advance clinical programs and portfolio, with $370.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Second Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics Inc. and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. dated October 7, 2022.

Exhibit 10.2 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Second Amendment to Collaboration and License Agreement (this ?Second Amendment?) amends the Collaboration and License Agree

First Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics Inc. and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. dated October 7, 2022.

Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This First Amendment to Collaboration and License Agreement (this ?Amendment?) amends the Collaboration and License Agreement date

Common Shares Sales Agreement, dated August 4, 2022, by and between and between Repare Therapeutics Inc. and Cowen and Company, LLC.

Exhibit 10.2 Repare therapeutics inc. Common Shares SALES AGREEMENT August 4, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Repare Therapeutics Inc., a corporation continued under the Business Corporations Act (Qu?bec) (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Sha

Up to $125,000,000 Common Shares

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257668 PROSPECTUS SUPPLEMENT (to Prospectus dated April 25, 2022) Up to $125,000,000 Common Shares We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to our common shares, no par value per share, offered by this prospectus supplement and the accompanying prospectus.

Collaboration and License Agreement by and between the registrant, Repare Therapeutics Inc. and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. dated June 1,2022.

Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential. COLLABORATION AND LICENSE AGREEMENT by and between REPARE THERAPEUTICS INC. and HOFFMANN-LA ROCHE INC. and F. HOFFMANN-LA ROCHE LT 272987170 v1 TABLE OF CONTENTS Page Article I Definiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Signed worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500) Repare rec

Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Signed worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500) Repare received a $125 million upfront payment in July 2022 as part of the collaboration agreement with Roche, and is eligible to receive up to an additional $1.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

RPTX / Repare Therapeutics Inc / Versant Venture Capital V, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 d325820dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* REPARE THERAPEUTICS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 760273102 (CUSIP Number) Ve

RPTX / Repare Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 4 TO THE SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga407422rptx06062022.htm AMENDMENT NO. 4 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no pa

Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential development

Exhibit 99.1 Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential development, regulatory, commercial and sales milestones, plus royalties on global net product sales. Repare to host conference call today at 5:00 p

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results Oral presentation of clinical data from the Phase 1/2 TRESR Trial of camonsertib (also known as RP-3500) monotherapy in solid tumors at 2022 AACR Annual Mee

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results Oral presentation of clinical data from the Phase 1/2 TRESR Trial of camonsertib (also known as RP-3500) monotherapy in solid tumors at 2022 AACR Annual Meeting Results demonstrated robust activity in ovarian cancer with a 75% CBR, 25% ORR and 35 weeks mPFS Results also show 43% CBR in solid

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

As filed with the Securities and Exchange Commission on March 11, 2022

As filed with the Securities and Exchange Commission on March 11, 2022 Registration No.

Filing fee table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 Repare Therapeutics Inc. Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, no par value per share, 2020 Equity Incentive Plan Other (

As filed with the Securities and Exchange Commission on March 7, 2022

As filed with the Securities and Exchange Commission on March 7, 2022 Registration No.

Post-Effective Amendment No. 2

Table of Contents As filed with the Securities and Exchange Commission on March 2, 2022 Registration No.

Commencement Date Memorandum to the Lease Agreement by and between the registrant, Repare Therapeutics Inc. and RREF America REIT II Corp. PPP, dated February 25, 2022.

EXHIBIT 10.28 COMMENCEMENT DATE MEMORANDUM THIS MEMORANDUM, made as of February 25, 2021, by and between RREEF AMERICA REIT II CORP. PPP, a Maryland corporation (?Landlord?) and REPARE THERAPEUTICS USA, INC, a Delaware corporation (?Tenant?). Recitals: (a) Landlord and Tenant are parties to that certain Lease, dated for reference July 13, 2021 (the ?Lease?) for certain premises (the ?Premises?) co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi

Employment Agreement between the registrant and Steve Forte, dated June 12, 2020.

EXHIBIT 10.11 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into as of June 12, 2020, by and between Steve Forte (the ?Executive?) and Repare Therapeutics Inc. (the ?Company?). WHEREAS, the Company and the Executive wish to enter into this Agreement to set forth the terms and conditions of the Executive?s continued employment with the Company effective and conditional

Fifth Amendment to Lease Agreement by and between the registrant, Repare Therapeutics Inc. and The Manufacturers Life Insurance Company, dated January 17, 2022.

EXHIBIT 10.27 FIFTH (5TH) AMENDMENT TO LEASE AGREEMENT THIS FIFTH AMENDMENT TO LEASE AGREEMENT made this January-17-2022 BETWEEN: THE MANUFACTURERS LIFE INSURANCE COMPANY (hereinafter called the "Landlord") OF THE FIRST PART, AND REPARE THERAPEUTICS INC. (hereinafter called the "Tenant") OF THE SECOND PART, WHEREAS pursuant to a Lease dated the 15th day of May, 2014 (the "Original Lease") between

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results Cambridge, MA & Montreal, QC, March 1, 2022 (BUSINESS WIRE) - Repare Therapeutics Inc. (?Repare? or the ?Company?) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of nov

As filed with the Securities and Exchange Commission on March 1, 2022

Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therap

Filing Fee Table

EX-FILING FEES 5 d320821dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 Repare Therapeutics Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common shares, n

RPTX / Repare Therapeutics Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, no par value, of Repare Therapeutics Inc., which may

RPTX / Repare Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31,

RPTX / Repare Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Repare therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

RPTX / Repare Therapeutics Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment

SC 13G/A 1 rptxa121122.htm CHI ADVISORS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Repare Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the a

RPTX / Repare Therapeutics Inc / ARK Investment Management LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commis

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022

Exhibit 99.1 Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022 Cambridge, MA & Montreal, QC, January 7, 2022 (BUSINESS WIRE) ? Repare Therapeutics Inc. (?Repare? or the ?Company?) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeu

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Repare Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Quebec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Oral presentation of initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference Results demonstrated favorable and differentiated safety p

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Oral presentation of initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference Results demonstrated favorable and differentiated safety profile, along with promising early activity, for RP-3500 in patients with a range of synthetic-lethal genomic alterations Gross Proceeds

First Amendment to Research Services, License and Collaboration Agreement by and between the registrant and Ono Pharmaceutical Co., Ltd., dated October 29, 2021.

Exhibit 10.1 FIRST AMENDMENT TO RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT This First Amendment to Research Services, License and Collaboration Agreement (this ?First Amendment?) is entered into as of October 29, 2021 (the ?First Amendment Effective Date?) by and between Repare Therapeutics, Inc., a corporation organized and existing under the laws of Canada and having its principal pl

RPTX / Repare Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Repare Therapeutics Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 760273102 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-640

LOCK-UP AGREEMENT

LOCK-UP AGREEMENT October 26, 2021 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule I to the Underwriting Agreement referred to below c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o Cowen and Company, LLC

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 2, 2021, with respect to the ordinary shares of Repare Therapeutics Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 (October 27, 2021) Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Inc

Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares

Exhibit 99.2 Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares Cambridge, Mass. & Montreal, Quebec, October 27, 2021 ? Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offe

Repare Therapeutics Announces Proposed Public Offering of Common Shares

Exhibit 99.1 Repare Therapeutics Announces Proposed Public Offering of Common Shares Cambridge, Mass & Montreal, Quebec, October 27, 2021 ? Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public off

Underwriting Agreement, dated October 27, 2021, by and among Repare Therapeutics Inc. and Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters named therein

Exhibit 1.1 Execution Version 4,000,000 Shares REPARE THERAPEUTICS INC. COMMON SHARES (NO PAR VALUE) UNDERWRITING AGREEMENT October 27, 2021 October 27, 2021 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Gold

RPTX / Repare Therapeutics Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common shares, no par valu

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257668 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common shares, no par value 4,600,000 $22.00 $101,200,000 $9,382 (1) Includes 600,000 common shar

$75,000,000 Common Shares

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257668 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Initia

Exhibit 99.1 Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics? SNIPRx platform for molecular selection of tumors for th

Repare Therapeutics Appoints Thomas Civik to its Board and as New Chairman Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx

Repare Therapeutics Appoints Thomas Civik to its Board and as New Chairman Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx CAMBRIDGE, Mass.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 (September 6, 2021) Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of I

RPTX / Repare Therapeutics Inc / Versant Venture Capital V, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* REPARE THERAPEUTICS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 760273102 (CUSIP Number) Versant Venture Capital V, L.P. R

Third Amendment to Lease Agreement by and between the registrant, Repare Therapeutics Inc. and NEOMED Institute, dated June 1, 2021.

Exhibit 10.2 LEASE AMENDMENT AGREEMENT dated effective June 1, 2021. BY AND BETWEEN : NEOMED INSTITUTE, a corporation governed by the Canada Not-for-profit Corporations Act, having its principal place of business at 7171, Frederick-Banting Street, Saint-Laurent, Province of Qu?bec, H4S 1Z9; (the ?Lessor?) AND: REPARE THERAPEUTICS INC., a corporation duly incorporated under the Canada Business Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Lease Agreement by and between the registrant, Repare Therapeutics Inc. and RREEF America REIT II Corp. PPP , dated July 31, 2021.

Exhibit 10.4 11/02 SOG(BY)-INS Revised 12/05 LEASE RREEF AMERICA REIT II CORP. PPP, Landlord, and REPARE THERAPEUTICS USA INC., Tenant Riverfront Office Park Cambridge, Massachusetts TABLE OF CONTENTS (continued) Page 1. USE AND RESTRICTIONS ON USE 1 2. TERM 2 3. RENT 3 4. RENT ADJUSTMENTS 3 5. SECURITY DEPOSIT 5 6. ALTERATIONS 6 7. REPAIR 7 8. LIENS 7 9. ASSIGNMENT AND SUBLETTING 7 10. INDEMNIFIC

Fourth Amendment to Lease Agreement by and between the registrant, Repare Therapeutics Inc. and The Manufacturers Life Insurance Company, dated June 22, 2021.

Exhibit 10.3 FOURTH (4TH) AMENDMENT TO LEASE AGREEMENT THIS FOURTH AMENDMENT TO LEASE AGREEMENT made this Jun-22-2021 BETWEEN: THE MANUFACTURERS LIFE INSURANCE COMPANY (hereinafter called the "Landlord") OF THE FIRST PART, and REPARE THERAPEUTICS INC. (hereinafter called the "Tenant") OF THE SECOND PART, WHEREAS pursuant to a Lease dated the 15th day of May, 2014 (the "Original Lease") between CIG

Addendum to Lease Agreement by and between the registrant, Repare Therapeutics Inc. and NEOMED Institute, dated June 1, 2021.

Exhibit10.1 ADDENDUM TO THE LEASE AGREEMENT SIGNED ON JUNE 1st, 2021 BETWEEN: NEOMED INSTITUTE, duly incorporated under Canada Not-for-profit Corporations act, having received its certificate of incorporation on November 16, 2012, with its head office at 7171, Frederick-Banting, City of Montreal, judicial district of Montreal, Province of Quebec, H4S 1Z9, herein acting and represented by Matthew C

Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results Announced dosing of first patient in Phase 1b/2 ATTACC trial of ATR inhibitor RP-3500 and PARP inhibitor combinations in patients with molecularly selected

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results Announced dosing of first patient in Phase 1b/2 ATTACC trial of ATR inhibitor RP-3500 and PARP inhibitor combinations in patients with molecularly selected cancers Planning disclosure of initial monotherapy data from the Phase 1/2 TRESR RP-3500 clinical trial early in 4Q21 Announced dosing o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss

RPTX / Repare Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Repare Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 760273102 (CUSIP Number) Ansbert Gadicke MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Nu

Joint Filing Statement

Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc.

Form of Common Share Warrant Agreement and Warrant Certificate.

Exhibit 4.7 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF COMMON SHARE WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF COMMON SHARE WARRANT AGREEMENT THIS COMMON SHARE WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between REPARE THERAPEUTICS INC., a corporation existing under the laws of the province of Qu?bec (the ?Company?), and [?], a [corporation] [national ba

Form of Indenture between the Registrant and one or more trustees to be named.

Exhibit 4.5 REPARE THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Se

Form of Preferred Share Warrant Agreement and Warrant Certificate.

Exhibit 4.8 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF PREFERRED SHARE WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF PREFERRED SHARE WARRANT AGREEMENT THIS PREFERRED SHARE WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between REPARE THERAPEUTICS INC., a corporation existing under the laws of the province of Qu?bec (the ?Company?), and [?], a [corporation] [na

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.9 REPARE THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF REPARE THERAPEUTICS INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REPARE THERAPEUTICS INC., a corporation organized under the laws of the province of Québec (the “Company”), and [•], a [corporation] [n

Power of Attorney (included on signature page).

As filed with the Securities and Exchange Commission on July 2, 2021 Registration No.

Joint Filing Statement

EX-99.C 2 d189567dex99c.htm EX-99.C Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc. is filed on behalf of each of the undersigned. Date: May 25, 2021 MPM BIOVENTURES 2014, L.P. By: MPM BioVentures 2

RPTX / Repare Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Repare Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 760273102 (CUSIP Number) Ansbert Gadicke MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of P

Submission of Matters to a Vote of Security Holders

8-K 1 d173927d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 (May 13, 2021) Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Québec 001-39335 Not applicable (State or Other Ju

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39335 Repare Therapeutics Inc.

Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results Introduced PKMYT1 as synthetic-lethal target for tumors with CCNE1 amplification or FBXW7 loss and highlighted program progress at RP-6306 Virtual Investor

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results Introduced PKMYT1 as synthetic-lethal target for tumors with CCNE1 amplification or FBXW7 loss and highlighted program progress at RP-6306 Virtual Investor Day Event Announced enrollment of first patient in RP-6306 Phase 1 clinical trial Activated 10 clinical trial sites across North America

Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event -Company highlights pre-clinical anti-tumor activity of RP-6306, a first-in-class, selective, oral inhibitor of PKMYT1, which is synthetic lethal with

Exhibit 99.1 Repare Therapeutics to Highlight Program Progress for RP-6306 at Today?s Virtual Investor Day Event -Company highlights pre-clinical anti-tumor activity of RP-6306, a first-in-class, selective, oral inhibitor of PKMYT1, which is synthetic lethal with CCNE1 amplification and other genomic mutations- - Initiation of Phase 1 clinical trial enrollment for RP-6306 anticipated to begin duri

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio

- S-8

As filed with the Securities and Exchange Commission on April 5, 2021 Registration No.

- DEFA14A

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Schedule 14A

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Repare Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) (CUSIP Number) An

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Repare Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 760273102 (CUSIP Number) Ansbert Gadicke MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Nu

Joint Filing Statement

EX-99.C Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Repare Therapeutics Inc. is filed on behalf of each of the undersigned. Date: March 22, 2021 MPM BIOVENTURES 2014, L.P. By: MPM BioVentures 2014 GP LLC, its General Pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) March 12, 20

Description of Registrant’s Securities.

EX-4.4 2 rptx-ex44737.htm EX-4.4 Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common shares of Repare Therapeutics Inc., a corporation organized under the Business Corporations Act (Québec), or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Initiated patient recruitment of PARP-inhibitor combination arm of RP-3500 TRESR Phase 1/2 clinical trial Initiated IND-enabling studies for

Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Initiated patient recruitment of PARP-inhibitor combination arm of RP-3500 TRESR Phase 1/2 clinical trial Initiated IND-enabling studies for RP-6306, the Company’s CCNE-1 synthetic-lethal inhibitor program Phase 1 clinical trial for RP-6306 is anticipated to commence in 2Q 2021

Third Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics USA Inc. and Bristol-Myers Squibb Company, dated November 20, 2020.

Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Third Amendment to Collaboration and License Agreement (this ?Third Amendment?) is entered into as of November 30, 2020 (the ?T

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Repare Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Repare Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* REP

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* REPARE THERAPEUTICS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 760273102 (CUSIP Number) Versant Venture Capital V, L.P. R

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, no par value, of Repare Therapeutics Inc., which may

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Repare therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) (CUSIP Number) December

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Repare therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Repare Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 760273102 (CUSIP Number) December 31,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* REP

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* REPARE THERAPEUTICS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 760273102 (CUSIP Number) Versant Venture Capital V, L.P. R

Second Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics USA Inc. and Bristol-Myers Squibb Company, dated September 24, 2020.

Exhibit 10.1 SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Second Amendment to Collaboration and License Agreement (this “Second Amendment”) is entered into as of September 24, 2020 (the “Second Amendment Effective Date”) by and between Repare Therapeutics Inc., a Canadian corporation with offices at 7210 Frederick- Banting, Suite 100, St. Laurent, Quebec, Canada H4S 2A1 (“Repare In

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) Qu?bec 001-39335 Not applicable (State or Other Jurisdiction of Incorporation) (Commi

Second Amendment to Lease Agreement by and between the registrant, the registrant and NEOMED Institute, dated June 11, 2020.

DocuSign Envelope ID: 7319D241-5AE6-4EFA-AAE4-D54C52D2572A Exhibit 10.2 LEASE AMENDMENT AGREEMENT dated June 11th, 2020. BY AND BETWEEN : NEOMED INSTITUTE, a corporation governed by the Canada Not-for-profit Corporations Act, having its principal place of business at 7171, Frederick-Banting Street, Saint-Laurent, Province of Québec, H4S 1Z9; (the “Lessor”) AND: REPARE THERAPEUTICS INC., a corporat

Repare Therapeutics Reports Third Quarter 2020 Financial Results and Operational Highlights – Initiated GLP toxicology studies for newly designated RP-6306, the Company’s CCNE-1 synthetic-lethal inhibitor program – Phase 1 clinical trial for RP-6306

Exhibit 99.1 Repare Therapeutics Reports Third Quarter 2020 Financial Results and Operational Highlights ? Initiated GLP toxicology studies for newly designated RP-6306, the Company?s CCNE-1 synthetic-lethal inhibitor program ? Phase 1 clinical trial for RP-6306 is anticipated to commence in Q3 2021, reflecting an accelerated timeline from prior guidance ? Initiated a Phase 1/2 clinical trial for